

Myrbetriq® (mirabegron) – Expanded indication

- On April 27, 2018, the FDA approved Astellas' <u>Myrbetriq (mirabegron)</u>, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in combination with the muscarinic antagonist <u>Vesicare</u> (solifenacin).
 - Previously, Myrbetriq was approved for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency.
- The efficacy of Myrbetriq in combination with Vesicare was demonstrated in two, 12-week studies. In the first study, patients were randomized to placebo, Vesicare 5 mg, Myrbetriq 25 mg, Myrbetriq 50 mg, Vesicare 5 mg plus Myrbetriq 25 mg, or Vesicare 5 mg plus Myrbetriq 50 mg once daily. In the second study, patients were randomized to Vesicare 5 mg, Vesicare 10 mg, or Vesicare 5 mg plus Myrbetriq 25 mg (increased to 50 mg at 4 weeks) once daily.
 - In the first study, the difference in the number of incontinence episodes per 24 hours were 0.25 (95% CI: -0.49, -0.01) and -0.34 (95% CI: -0.58, -0.10) for the combination Myrbetriq 25 mg group vs. Vesicare group and vs. Myrbetriq 25 mg group, respectively, and -0.20 (95% CI: -0.44, 0.04) and -0.23 (95% CI: -0.47, 0.01) for the combination Myrbetriq 50 mg group vs. Vesicare group and vs. Myrbetriq 50 mg group, respectively.
 - In the first study, the difference in the number of micturitions per 24 hours were -0.29 (95% CI: -0.57, -0.01) and -0.39 (95% CI: -0.67, -0.11) for the combination Myrbetriq 25 mg group vs. Vesicare group and vs. Myrbetriq 25 mg group, respectively, and -0.48 (95% CI: -0.78, -0.21) and -0.58 (95% CI: -0.84, -0.28) for the combination Myrbetriq 50 mg group vs. Vesicare group and vs. Myrbetriq 50 mg group, respectively.
 - In the second study, the change from baseline in the number of incontinence episodes per 24 hours was -1.53 for the Vesicare 5 mg group vs. -1.80 for the combination Myrbetriq/Vesicare group (difference: -0.26 [95% CI: -0.47, -0.05]).
- The recommended starting doses for combination treatment are Myrbetriq 25 mg orally once daily and Vesicare 5 mg orally once daily. Based on individual patient efficacy and tolerability, the Myrbetriq dose may be increased to 50 mg once daily after 4 to 8 weeks.
 - The recommended starting dose of Myrbetriq monotherapy is 25 mg orally once daily with or without food. Myrbetriq 25 mg is effective within 8 weeks. Based on individual patient efficacy and tolerability the dose may be increased to 50 mg once daily.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.